Morimoto, CEO, Delivers Special Lecture at “Growth Strategy for Healthcare Annual Forum 2026,” Attended by Nobel Laureates, Ministers, and 500 CEOs, Leaders from Industry, Academia, and Government

Tokyo, Japan, June 2, 2026 - FRONTEO, Inc. (Headquarters: Tokyo, Japan; President & CEO: Masahiro Morimoto; hereinafter “FRONTEO”) is pleased to announce that President & CEO Masahiro Morimoto has been invited to deliver a special lecture at “Growth Strategy for Healthcare Annual Forum 2026” produced by Innovation for Healthcare, Inc., to be held on Wednesday, July 15, 2026, at the International House of Japan (Minato-ku, Tokyo). Following the special lecture, Hiroyoshi Toyoshiba, Director/CSO (Chief Science Officer) of FRONTEO, will also participate in the panel discussion.

“Growth Strategy for Healthcare Annual Forum 2026”

“Growth Strategy for Healthcare” is an exclusive innovation platform for CEOs, and C-level executives in pharmaceutical, healthcare industry, government top officials, and top doctors/ researchers, which was launched in 1993 under the guidance of Teijiro Furukawa, former Deputy Chief Cabinet Secretary, who is a legendary figure in Japanese healthcare, and Toshikatsu Fujii, former CEO of Innovation for Healthcare, Inc. With a 33-year history and over 396 sessions held to date, it is a unique strategic platform for top leaders from industry, academia, and government in Japan’s healthcare sector. Chaired by Osamu Nagayama, Honorary Chairman of Chugai Pharmaceutical, the forum is led by a strategic team of 10 top leaders from industry, academia, and government. Past speakers include top government officials such as Ministers, Vice Ministers of the Cabinet Office, Deputy Ministers of Health, Labour and Welfare, and Ministers of Health, Labour and Welfare—as well as Chairman, and CEOs of leading pharmaceutical, healthcare related companies, and world-renowned researchers.

Growth Strategy for Healthcare Annual Forum 2026 is the largest annual strategic conference, bringing together 500 top leaders from industry, academia, and government, including CEOs and senior executives from the pharmaceutical, medical device, healthcare, wholesale, trading, IT, finance, and venture capital sectors, as well as top government officials from the Ministry of Health, Labour and Welfare and other ministries, and leading researchers, clinicians, and hospital board chairs. Speakers for each session are carefully selected based on their world-class achievements in their respective fields.

For this forum’s special lectures, President and CEO of FRONTEO, Morimoto, has been selected to speak alongside Shimon Sakaguchi, Distinguished Honorary Professor of the University of Osaka and Nobel Laureate in Physiology or Medicine. The keynote speech will be delivered by Ryozo Nagai, President of Jichi Medical University, Professor Emeritus at the University of Tokyo, and Chief Medical Officer to the Imperial Household Agency.

The theme of Morimoto’s presentation is “Measures to Strengthen Japan’s Drug Discovery Capabilities: Innovative Drug Discovery Using Equation-Driven, Domestically Developed AI.” He will discuss how to strengthen Japan’s drug discovery capabilities through the deployment of “Drug Discovery AI Factory (DDAIF),” an AI-driven drug discovery support service centered on “KIBIT*,” an equation-driven AI developed in-house by FRONTEO.

Following this presentation, a panel discussion will feature Hitoshi Iikura, Director, Executive Vice President at Chugai Pharmaceutical; Toshihiko Takeda, former Policy Advisor to the Cabinet Secretariat; and from FRONTEO, Morimoto and Toyoshiba. They will explore the strategic use of AI and the development of a robust drug discovery ecosystem essential for Japan to sustain its global competitiveness.

[Event Overview]

Title: “Growth Strategy for Healthcare Annual Forum 2026” by Innovation for Healthcare, Inc.
Date and Time: Wednesday, July 15, 2026, 16:30 – 21:15
Venue: International House of Japan (5-11-16 Roppongi, Minato-ku, Tokyo) / Online, hybrid event
Target Audience: Primarily pharmaceutical and medical device manufacturers, healthcare-related industries, IT, finance, government officials, and experts and leaders in medical and research fields. Please note that the secretariat reserves the right to decline participation if an applicant is deemed ineligible based on the forum’s purpose and operational policies.
Capacity: 250 on-site / 250 online, total 500
Participation Fee: 23,000 yen (on-site) / 16,000 yen (online)
Details on Registration and Participation Requirements: https://innovationforhealthcare-annualforum2026.peatix.com/view
Organizer: Innovation for Healthcare, Inc. Secretariat of “Growth Strategy for Healthcare”
※Please note that forum will be held in Japanese.

[Program]
16:30 – 16:50 Opening Remarks:
　Yuriko Fujii (CEO, Innovation for Healthcare, Inc. / Founder, Growth Strategy for Healthcare)
　Osamu Nagayama (Honorary Chairman, Chugai Pharmaceutical / Chairman, Growth Strategy for Healthcare)
　Kenichiro Ueno (Minister of Health, Labour and Welfare)
　Hisashi Matsumoto (Minister of Digital Transformation)
　Masato Iwasaki (Former Representative Director, Takeda Pharmaceutical / Senior Advisor, Growth Strategy for Healthcare)

16:50 – 17:35 Keynote Speech:
　Ryozo Nagai (President, Jichi Medical University; Professor Emeritus, The University of Tokyo; Chief Medical Officer, Imperial Household Agency)

17:35 – 18:35 Special Lecture:
　Shimon Sakaguchi (Nobel Laureate /Distinguished Honorary Professor of the University of Osaka)

18:35 – 19:05 Panel Discussion:
　Shimon Sakaguchi
　Hiroyuki Mano (President, National Cancer Center)
　Yasuhiro Fujiwara (President, Pharmaceuticals and Medical Devices Agency [PMDA])
　Masato Iwasaki

19:05 – 19:45 Special Lecture:
　Masahiro Morimoto (President and CEO, FRONTEO)

19:45 – 20:15 Panel Discussion:
　Masahiro Morimoto
　Hiroyoshi Toyoshiba (Director/CSO (Chief Science Officer), FRONTEO)
　Hitoshi Iikura (Director, Executive Vice President, Chugai Pharmaceutical)
　Toshihiko Takeda (Former Policy Advisor to the Cabinet Secretariat, Senior Advisor, Growth Strategy for Healthcare)

20:15 – 20:25 Group Photo / Move to Next Venue

20:25 – 21:15 Reception & Networking

*Equation-driven AI “KIBIT” is an artificial intelligence independently developed by FRONTEO. By utilizing mathematical equations, KIBIT enables discontinuous discoveries, identification of causal relationships, and highly accurate, reproducible analyses. Its lightweight learning process allows it to operate on a single personal computer. Patents have been granted in Japan, the U.S., and Europe.

【Mission of “Growth Strategy for Healthcare” produced by Innovation for Healthcare, Inc.】

“Growth Strategy for Healthcare” is an exclusive innovation platform for CEOs, C-level executives, and leaders from industry, academia, and government. Launched in 1993 under the guidance of Teijiro Furukawa, former Deputy Chief Cabinet Secretary, and Toshikatsu Fujii, former CEO of Innovation for Healthcare, Inc. It has been held monthly for 33 years, driven by the legacy of two generations of Harvard Business School alumni at Innovation for Healthcare, Inc. Empowering the industry with precision and foresight: Its mission is to provide comprehensive industry forecasts, unparalleled insights from leading government officials and industry pioneers, and exclusive opportunities for collaboration and innovation.

It is currently operated by a group of 10 leaders, including Osamu Nagayama, Honorary Chairman of Chugai Pharmaceutical; Yasuo Otani, former Deputy Minister of Health, Labour and Welfare; Masato Iwasaki, former Representative Director of Takeda Pharmaceutical; Toshihiko Takeda, former Policy Advisor to the Cabinet Secretariat; and Yuriko Fujii, CEO of Innovation for Healthcare, Inc. In addition to CEOs and senior executives from the healthcare industry, the seminar is attended by national-level decision-makers such as the current Minister and Director-General of Medical Affairs at the Ministry of Health, Labour and Welfare.

Drawing inspiration from the Harvard Business School case method, this seminar is designed not merely as a “platform for receiving knowledge,” but as a “platform for applying knowledge, refining decision-making, and shaping strategy.”

The seminar has facilitated practical discussions on issues that will determine the future of Japan’s healthcare industry, including healthcare financing, drug pricing, social security systems, the background of policy formation, healthcare DX, AI and data strategies, strengthening drug discovery and R&D capabilities, changes in industrial structure, new business opportunities, and international trends.

The seminar has generated outcomes that have led to new collaborations, business creation, and the emergence of global companies, thereby contributing to the development of Japan’s healthcare industry.

This seminar continues to evolve as a unique innovation platform where top leaders from industry, academia, and government in the healthcare sector gather to co-create the future through candid discussions, providing “immediately applicable knowledge and high-level networks” that span all three sectors.

[Strategic Team of “Growth Strategy for Healthcare”]

• Osamu Nagayama (Honorary Chairman, Chugai Pharmaceutical)
• Yasuo Otani (Chairman, Kanagawa University of Human Services / former Deputy Minister of Health, Labour and Welfare / First Director of AMED)
• Toshihiko Takeda (Former Policy Advisor, Cabinet Secretariat)
• Masato Iwasaki (Former Representative Director, Takeda Pharmaceutical Company Limited)
• Koji Miura (Professor by Special Appointment, Fujita Health University / Former Director-General of the Health and Welfare Bureau)
• Norikazu Eiki (Former Chairman and Representative Director, Bayer Yakuhin)
• Keita Nishiyama (Visiting Professor, Institute for Future Initiatives, The University of Tokyo / Former Director-General, Ministry of Economy, Trade and Industry)
• Shinsuke Muto (Chairman, Integrity Healthcare, Inc. / Physician)
• Fumiaki Ikeno (Senior Researcher, Stanford University / Physician)
• Yuriko Fujii (CEO, Innovation for Healthcare, Inc.)

About FRONTEO Drug Discovery AI Factory (DDAIF)

[Reference: Initiatives with pharmaceutical companies and Academia]
https://www.fronteo.com/news/ddaif-list

FRONTEO Drug Discovery AI Factory (DDAIF) is an AI-based drug discovery support service that combines KIBIT (patented in Japan, Europe, the U.S., and South Korea), an Equation-driven AI specialized in natural language processing, with the expertise of FRONTEO’s drug discovery researchers and AI engineers. It powerfully supports researchers’ decision-making in drug development through the analysis of disease-related gene networks and the construction of hypotheses regarding target molecule candidates. This service has already been adopted by multiple major pharmaceutical companies and has a proven track record.

*The technology used in Drug Discovery AI Factory is covered by a total of 21 patents held by FRONTEO in Japan, Europe, the U.S., and South Korea.

https://lifescience.fronteo.com/products/drug-discovery-ai-factory/

About FRONTEO, Inc. https://www.fronteo.com/en/